Lunai Bioworks Inc. (LNAI): Nasdaq/NYSE listing notice — Enochian Biosciences receives Nasdaq deficiency notice for bid price below $1.00

Lunai Bioworks Inc.

Received Nasdaq deficiency notice on July 7, 2023, for failing minimum bid price requirement.
Closing bid price below $1.00 for 30 consecutive business days prior to notice.
Has 180 days, until January 3, 2024, to regain compliance by closing at $1.00+ for 10 consecutive days.
If not compliant by Jan 3, 2024, may be eligible for an additional 180-day period if other standards are met.
Company is monitoring bid price and considering options to regain compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

July 7, 2023, Enochian Biosciences Inc. (the “ Company ”) received a deficiency notice from The Nasdaq Stock Market (“ Nasdaq ”) informing the Company that its common stock, par value $0.0001 per share (the “ Common Stock ”), fails to comply with the $1 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) based upon the closing bid price of the Common Stock for the 30 consecutive business days prior to the date of the notice from Nasdaq. Nasdaq’s notice has no immediate effect on the listing of the Common Stock on The Nasdaq Capital

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Lunai Bioworks Inc. filing history →

Source: SEC EDGAR

accession 0001731122-23-001290

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.